AWH - Earnings call transcript Q4 2020 | Aspira Women's Health Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, ladies and gentlemen, and welcome to Aspira Women's Health Fourth Quarter 2020 Conference Call. My name is Laura, and I will be your coordinator for the call today. At this time, all participants are in a listen-only mode.

Following management's prepared remarks, we will open the call for your questions.

As a reminder, this conference is being recorded. are Chief President Zagger, Financial Officer; today Officer; Chief Chief call Dr. Beechey, Bob Officer; the Valerie and Palmieri, Executive Operating Leading and Kaile Dr. Chief Officer; Northrop, and Lesley Scientific Clinical Elena and Ratner, Medical Global Advisor Translational Chief Medicine. and After for call open Q&A. the remarks, prepared will the we

this defined Aspira's future begin, during as expected forward-looking the future prospects would or future or Litigation of statements I Q&A plans Reform statements the we XXXX. to remind performance, including Before that Private Securities session, events are everyone under like made call, relating to Act business

forth I reflected Although reasonable the in company the to in results and President results believes such outcomes materially those actual quarter could statements that are upon differ from you to due begin. the this to third from you, based and Executive to anticipated risks as expectations may uncertainties Officer. are cause forward-looking in and the the Report that whether cautionary Chief note as call or and for the and subject result future Aspira's Annual forward-looking like factors anticipated set in assumptions, materially many At Aspira. today's statements. time, to otherwise. differ directed over the to to Palmieri, of Participants would risk SEC turn the Valerie Valerie, factors thank obligation no information, beyond the The could a release, filed forth with statements or well XX-Q actual as press set assumes impact supplement forward-looking are events update of control of new any company factors, those

Valerie Palmieri

performance, launch, accomplishments, you and year QX product developments we strategic This fourth review you, our quarter payer of acceleration as terms and on financial a Operator. update will thank XXXX for us an joining today. coverage. Good as an afternoon, Thank everyone, in a afternoon, our of full our well and agreement

our Chief Zagger, executive members team, two Advisor introducing and Kaile Global Chief our Officer. Medical Clinical Dr. will I of our addition, Ratner, Operating of and In Elena of newest be Medicine Translational

are first and have the made announcing during launch to based advancements half the XXXX of the the I now in Sandford, our addition unmet Vice Executive on five appointees of which Vice appointed date Hospitals Nicole feel Officer Sandra now prior Nic executive algorithm. recently like move and her would expertise risk also as Brooks the of Jefferson operational of in a practice. field target leader Senior But President managing majority technology review. especially of Brooks, And would the Global is Chief help a in and to need, new the to on as to to tremendous thought currently to members at This our level. us I we regulatory C.P.A., launch board we the well, she a Thomas our equity. pandemic, Services OVASight before also of In Medical at and is partner board team Dr. MD role, bring next quarter to XX%, into that the the Both is originally the recent Ellig we and I the this President Board XXXX. the our investments planned comprised some our quarter Sandford. board a in and we note and health female Deloitte's was of health first as XXXX. you additions, Leader was developments company. acceleration national market Dr. Group. is woman's fourth update to like additional company two regarded for as University Today, important take to Directors

disease named OVANex prevalence million planned a This patients physicians total for with low previously ahead per population launch year. X which available mass to patients to and X.X has are a market, of a a designed able is pelvic monitor were times we will schedule. in not So for that a specifically allow surgery. OVAXplus, was test, of of which who is This

population I technology a with add announce for for ovarian State significant we entered we a was now announced and a to Last which March, coverage risk population potential Women's York of to for base for unlike combination is Advancing an Number with and Health OVAX based the intend which Hospital research strengthen for coupled Second, state. on cancer New price, congressional Medical XX% assessment into a the this covered in US to technology strategic in XX% total performance. have finally, of we covered lives significant effectively by the largest Institute, titled, have and use which to Number high executive pandemic development April populations is collaboration made a non-Caucasian million lives solid volume our test. with to lastly, The the Medicaid, as we but stage significant And am current in employees this how the agreement Outcomes novel position. They specificity and offering women briefing diagnostic, Dr. added to Minorities. we the York will our risk million, Cancer our public for published XXXX growth, details significantly of covering section. This demonstrated fund detection has cover and very our of happy technology. to collaboration one delivered of imagined, $XX Caucasian a X, panel, Medicaid our high weathered the We care key XXXX. as board, I additions Farber function population Brigham test am XXX cancer University last so we strong in am storm. month, more in the underserved three, New could risk the and ovarian of oversubscribed a proud at was will Northrop this the the need Lodz. of four, and and and US, Women call for commercialization as Dana financial delivered standard by for recap our and or moving to presented believe action completed medical screening to the her the teams. and be and early race of to ethnicity trials. high our our year brings we've sensitivity serve I anything an the large ever collectively in microRNA of women. improved We We test

included our we major year agreement South coverage added continue an seven our to OVAX also adding and position milestones. We Jersey during Medicaid payor, as national This panels, Georgia, our XX to genetic million of and added addition payor very state financial contracted contract states to pipeline with and GenetiX. and strengthen rates. advance testing cancer our ovarian to plans agreement. favorable additional to our This network Highlights one, known New CIGNA the is Number were added we Carolina. XXXX. major received with addition first plans, our the lives product and well of XXXX new in last Number in-network two, our XX Aspira includes as

that now media the today is campaign, addition for and is sensitivity at stands early With of to Medicaid managing ovarian cancer detection the in credentialed Number only detection New of ovarian risk our technology we has coverage XX% cancer awareness continue digital we the superior lives, to Medicaid this ovarian so increase population. the specifically total OVAX the our cancer the available of of technology black its population underserved population our million performance women. relative place detection critical in and XX black which as three, US is to and population. York, in Having the believe both of and CA-XXX through adequate

with These campaign data to a six, serve of FDA Health. focus the a commitment Women's Aspira centered breakthrough patient-centric ovarian Dr. designation of In Spokeswoman, and we how company XXXX. submitted we and support elagolix on agreement also Number total a FDA dialog of have impressions. clinical our patients. with rebranded as lead internal Our successful Vermillion own from and the mission to entered agreed organization, and whose XXX Number total expect Chief into includes educate patient will we AbbVie. advisory metrics to first also media the media samples we XXXX, our for AbbVie second on the survivors five, total from specimen provide we of in This XXX a the an quarter a formed with device four, rebranding million Number cancer is successfully collaboration trial. health. the The patients serum board specimens, women's led to to quarter of by Diane board, Powis. to had EndoCheck. development placements a application

addition, products to Synergy unprecedented and as technology rebranded GenetiX well. transfer In to Aspira we we during Aspira OVASight extraordinary two this And and times. executed year finally, OVANex

cover turn the the we of to to commercialization commercial I I Kaile, our Before momentum and call in had. over Aspira's detail, want will summarize progress investment who impact in the

over sequentially the grew by volume quarter fourth quarter Our third X%.

and In due strategic unit X% team, we Our an will which summary, stronger stronger emerge we've to to goal, continue volume cover overall growth, basis. work stronger expansion pandemic, believe per towards to pipeline. accomplished revenue XX% on Bob this position was our our the as was stronger detail. as a in financial from OVAX and up our with price well that we our

launched adoption. of and to across In seasoned positioned short whitespace commercial call that net industry to Kaile talent to my well is abilities Zagger, of spans and to We us building disrupting care Kaile to lives. transformation She multiple performance. preparing significantly business whose and most executive, healthcare turn standard with leadership It commercial of time, teams standard are to save new strategy optimize grow now adoption period a in elevating to healthcare verticals, and scale experience over operations disciplines. importantly, drive invest our a care is has extraordinary the brings senior pleasure for technologies a

he are to I'd Aspira Kaile. to introduce ranks We Health. executive to welcome like the thrilled of Women's

Kaile Zagger

commercial cancer. are Thank save this to women ovarian a very pipeline diseases our performed tenure, Undoubtedly, you, these of they Valerie. the healthcare plan important represents the positioned and In the products in we've of practitioners the the and care our will deep strategic of beginning late to of be by and one, community to to company, disrupt lifecycle will subsequently ways. leadership and our maximize with Number patient and stage intention I'm with on my optimize patient. gynecological of impact we overall the and of to analysis personal the was a can At lives investment standard standard to understanding which of position, the and excited the disease, commencement value XXX% repositioning to in have detection care of America bring and enhanced prior team that robust and sales strategically North this core part products of capture a me, early of the intercepting and unequivocally significant exponentially mission diagnosis. the following coverage order conversion. focus that

racial care markedly are access for our on on and we to are sales Medicaid disparities within team We in increase patients. the diligently with core focused coverage, our these focused accelerating

launched XXXX. team investment we've increasing a patients the as XX% by in the that to for Number of integrate complex be allergies these will as to systems owned various health be workflow our systems QX QX in pathways team cancer launch. physicians intersect and OVASight XX% that over environments ovarian sales technology of by well prepare our health scheduled will the growth clinical two, continued with systems across We integrate by into

comprised this that Number world-class within we system a customer customers, to matrix an strategy adoption for we drive organization. large. expertise. create motion This confident and are seamless informatics health with both experience team highly and have three, and informatics small of critical for team and four, experienced set integrations products. timely the clinicians all creating our workflows work for of are We Number will in our is integration

systems, blended of expanding the patients with we Number will drive platform. a have adoption health sharp our on decentralized into size care. which with it focus for We access are the platform. and commercial are create believe penetration, also Synergy horizontally systems, communications, is acceleration providers impeccable healthcare white glove this be platform, on service We of intention of of providing this organization growth for Aspira alike. and and rapid future optimal pipeline ease and and to the an a the differentiator physician commercialized of labs our This Synergy is line cutting-edge top continuum contributor redeployed expand verticals of growth. will our all clinics. technology force penetration sales and products five, use products strong across focused All our be innovation to will connected of transfer experience synergy rapid and

We and GenetiX of activation are standard to to adoption are the growth finally, for as offering. the the awareness be will And the a is both and the care and market solution for commercial growth allow cornerstones poised for critical now They OVAXplus behind strategy of sales organization. greater our glue population. fuel of

by this Dr. simultaneously organization the patient action the focus the health have and key campaigns placed multiple the and across the constituents and days nature we've in around advisory center marketing horrific with At XX our the call built as continuum strategy, to such amplified past journey patient have strong while Diane of the the and the channels. our insurance This led ovarian bring of We life, board board experience Powis, Spokeswoman. to cancer to working across community. magnify is FDA Chief driving

would how into in teams insight the I performing and QX. like offer to to Now QX an pivot performance are

delivered we due fourth the volume In in we also to These in patients our the quarter February, territories. in some X% restrictions. inclement growth first mentioned, experienced COVID-XX context and of Valerie disruptions sales As and the sequential restrictions weather. delivery quarter continued continued

will recedes. to very We similar these traction build volume compounding are a believe impact QX QX strategies in a pickup to pandemic are the transformation the as March momentum volume to in factors of track We in pace. terms to gaining of seeing expect and due and at the begin strong

the and X,XXX expanded growth of has the for OVAXplus stickiness physicians In pre-COVID we portfolio. levels to update technology terms consistent Dr. of illustrates we prior signaling clearly quarter have and rate. the the QX. from providers run technology our our being care, would an repeat like opportunity with X% physicians XX% ordered of third the ordering on the retention with quarter, innovation over call with physicians impact now of Northrop the patient This providers, the to pipeline. on the increased back to year-over-year, to hand ordering provide The and flat our in number are I overall

Lesley Northrop

on enhancements. like Thank everyone. to a you, our brief and upcoming Kaile. would products provide afternoon, update Good I

risk screening is years expertise comprised As of previously discussed, with a our OVASight. young are over we risk creating high-risk adults starting XX entire that which hereditary of to OVAInherit a monitoring impact cancer risk in OVAXplus. products for with our portfolio, ovarian lifecycle diagnostic cancer assessment, EndoCheck surgery woman's with to to prior lastly, mass including assessment cancer And benign GenetiX, ovarian

detection. in the efforts We are investment disparity key the our of cancer continuing is R&D our increase women's and to gap one ovarian specific closing on to accuracy of in our healthcare, investments diagnostic

Detroit, national Michigan, cancer institute State addition We have sites the five clinical our our active as recent University, site. in Wayne most study, enrolled was disparity first

we are efforts. and study current to Philippines of our we and actively population and are soon, so pan-ethnic all future the the we to track multiple of goal ending of still this first The for manuscript black, data OVERA and the It the OVAX on timeline Asians capture our recruit on in populations, half products Israel. continuing that our our these Hispanic, is Our such imperative, Both the as publication sites end the sites are well publish into as for women and is from study as year. OVASight of to study products of studies, additional enrich clinical continue In working is XXXX. by international parallel, ethnic focused. completing

second risk investment on branded ovarian Our our assessment which generation third OVASight. as test, cancer now is is key

year, test today We a to pelvic present are risk availability mass. pleased was to announce our in are suspected full to launch clinical This the the who offer by women, the that date this driven with need fourth we now accelerating national all in of assessment quarter XXXX. for belief with

masses abstract to that classify it allows risk low surgery clearly not pandemic, to clinical help clear assessment an guide this test Society both of or and Clinical clinical June Oncology to submitted the the of early need. year, in the critical findings XXXX. We analytical During American conference for publishing and we'll requiring physicians management. their This as became QX be for a masses malignancy for is validation high of

their based symptoms providing progression surgical this dialog intended use the diagnosis received clinical clinical This to third first the EndoCheck. and management. device as endometriosis forego our of was of goal submitted EndoCheck We chronic direct studies FDA. well trial of we test data experiencing the is have elagolix time designation visualization population in early Currently, are now on will address GenetiX review allow my management want on that with the reduces by disease. aid surgery to an endometriosis and to CSO, from pain specimens diagnosed validation is will being for Aspira team of is We will the patient part The January, test there of The pain early in pelvic and be of endometriosis. as of XXX women population are breakthrough I early the known that leadership being chronic biopsy. test appropriate for platform the the is symptoms help indicative this who of our potentially an reassurance treated collected to by over and/or and evidence will are performance clinical cause this in second of prospectively product provide for non-surgical as real the exciting diagnosis a of the market test. Synergy from confirm is world blood-based launched our GenetiX. the believe and under innovation demand guide is pelvic endometriosis that

In valuable study. from reproductive network to will addition, entitled bank centers medicine we on a received NICHD efforts support six supported by and of consortium This These access study specimen EndoCheck. of the another funded specimens research. ENDOmarker was additional academic validation endometriosis

diagnostic specific to family inheritance. Additionally, of or an proof to of are OVAInherit to genetic a of test early cancer personal history, history risk due in test, predisposed concept we either ovarian our high population women

can OVASight has As Hospital in to sub-optimal ovarian are and and in proteins Institute, Dana diagnostic proteomic Lodz we early a sensitivity of of evaluating population. conjunction will of Brigham risk panel, potential CA-XXX, care microRNA diagnostic the combination detection and mentioned clinicians standard with Valerie, which Women's University earlier Currently, in with order specificity of technology Farber patient as transcriptomics and cancer. specificity Medical our cancer. the Cancer the current measurement by high this with sensitivity feel and ovarian of better ultrasound access We the provide outperform conjunction

very We innovation product are pipeline. the about excited

we With these aid XX a is worldwide. up to now are adults. masses health. EndoCheck states those diagnostic hereditary effect Valerie. a products, the and state is We overall EndoCheck goal XXX for like as to will the with a with be OVAInherit. understand endometriosis. young and ovarian modification as that by diagnosis help we surgery in core to moving improve OVAXplus early Evaluating acute a disease for for cancer like for This towards and for in the circling diagnosis the strategy planned early OVASight other women endometriosis test view, where with patients' degree that goal women's call To our treatment believe it as to with risk GenetiX product life-changing turn greater disease and enabling But with women monitoring in so, our Valerie? may disease. risk ensuring appropriate gynecologic do to cancers more at back we risk disease must starting one a would address cancer high prevent the provide I women an gynecologic of company of women

Valerie Palmieri

Thank you, Lesley.

reproductive Advisor introduce Bob Clinical our Gynecologic also of joined Ratner She mission Before is Elena Detection cure have the update Cancer Oncology Ovarian combating that Medical Translational part recently Early resonates to on our I Yale She serves and of is Chief would financials, Dr. Medicine. Ratner. Yale a greatly as School This at on Ratner? University of with focused Division Global Director of initiative an Dr. currently and team the provide Aspira's women's we Medicine. the Chief Program vision. cancers. Medicine's as Clinical discovery to Dr. like of initiative

Elena Ratner

Thank delighted am afternoon. the join you, to Valerie. this I call

great is to detection women ovarian is all truly mission of provide Aspira's to strive for cancer clinical health well and races, the of the for which disease. and the as patients and my patient unacceptable. changing ovarian to cancer considerable the the risk cancer disease. detection of research dismal practice assessment and and is enable of due narrative women ovarian core and ages, in and remains and survival the challenges of ethnicities of as cancer This inequities with management due survival ovarian improving early personalized Today, part cancer racial early

drive We women significantly color which access this, many to continue five-year order to There stage American early having detection is than lower risk especially cancer Caucasian technology best factors women. will but survival have assessment in improve critical. to the have rates are African

better to that the to and ages, test, And is of a yet, this ovarian is part cancer of in being urgent changing disease. the generations, great of disease. diagnosis, our fields the early due delay and for For great die of in funds early clear all This great of research serve the ovarian chance surgery from women the making and technology great has for it in days detection and majority cancer in of stage cancer. patients being done deal races best chemotherapy of better invested future amount ethnicities the come still is

technology Bob? to the best equal for assessment to care is I of financial pathway care that of the part the review Bob institutional implement to turn to our every like patient access would risk at all over so personalized level results. goal and back solutions. a has call end is Our our providers the

Robert Beechey

here, our Good everyone. be I'm members. I welcome afternoon, team delighted Ratner. new Dr. to and you, Thank

performed administrative December performed due to third tests quarter. now the visits the for XX% an as X,XXX our As had was performed December compared and OVAX I'd X% travel in revenue OVAXplus improve and X,XXX volume fourth for tests was further volume December third was due sequential slightly as XX,XXXX, the commercialization increased Sales $X growth tests million price the to $X.X during ended ended XX% for million team. The ended December to primarily compared were and increase to increase increase expenses in as quarter. to to compared as an the like earlier expenditures OVAXplus to the tax quarter marketing This XXXX, grants related due the to the in RSU patient-doctor the $X.X quarter, as on which COVID as three to Research in XX% XX% units the months with continued million a cash primarily OVAXplus The were expenditures adjusted the on to in $XXX,XXX. fourth three Board installment were primarily in for was Synergy. level XX a ended months XXXX, Product arose development This costs some high bioinformatics, ended connection improved the to of quarter months level Aspira The due was from month to three in $X.X to three $X.X for for in and restrictions was defray improved in slightly board third higher margin prior Gross volume in well fourth driven increase quarter, and test as fees on quarter and a the we well we've Director per a compared increase. XXXX, realization. product by have make of financials. the $XXX,XXX, entertainment to to increase marketing period compared of XX, $XXX improvement environment. liabilities, commercial quarter price the is and as third restricted XXXX, comments in OVAXplus XX, and discussed, investments XX% sequential the stock legal in primarily General as development to quarter well $X.X year. the to third This test eased compared increase to to and volume OVASight, the OVAXplus a the investments quarter, increase increase. expenses awareness, expenses million increased December $XXX as primarily pandemic settled COVID-XX in due patients the increase profit million number third increase month investment million XX, compared XX% third and of in quarter. three

as strength fund was increased giving in one-time in proceeds believe well expenses. the marketing We million approximately settlement us and the completed fourth $XXX,XXX compared total XXXX, enables opportunities included our resulting Our $XX.X the utilization in investment cash prior cash. balance the quarter utilization after company $XX.X the approximately as the in million company. I'll X, now in secondary remaining of of before both turn R&D. The facing quarter properly units. to investment $X.X current discounts sheet year it quarter. stock and million and commercial the stock effect of with awareness, the underwriting related offering, to sequential but net We innovation the to back Valerie. to $X.X On increase fourth to The the in February restricted to cash commercial million ended cash in due was

Valerie Palmieri

enterprise growth cancer the earliest delivered technology and patient for on near burden you, lowering getting at and term we've to one right this In building well will record focus be strengthened women. of firmly right in proud XX% of the am what It's all to in sustainable greater we the vital our as is any than financial for for its the team stability, that is and our healthcare for board. inefficiencies more company our mortality dominated a Ovarian pathway. gender-specific let of and the growth, believe doctor for stage call our as Before female year that a mission cancer about is rate. and our We I me reproductive than strong deaths right value, company. a restate core and the system pipeline pandemic, we other care XXXX. strategy open finding Thank with our the all cancer the and This long-term. Q&A, achieved the the Bob we the the significant overall and by reducing accounts the cancer only optimistic

for the changing women. differentiation and are will believe term, work we importantly, gap assessment pelvic at products testing our close and the survival and detection the In standards with the coupled in mass helping in Our ovarian for We of the standard OVAXplus, risk are more we ovarian believe of care near care in cancer. forefront become of genetics the of disparity malignancies. detection

term, and the EndoCheck ahead moving For we OVAInherit. longer launches with of planned lastly, our are OVASight,

be We receive also and of best disparate believe racial socioeconomic and the the information in ethnic era every to women care that COVID importance all this background elevated that possible. actually disparities further of might new diagnostic and reduce ensure care

answer We questions. to call are your of open happy now the any Q&A and for Operator?

Operator

of comes the [Operator William Brian from Instructions] Our line Weinstein first Blair. question with

question. your with proceed may You

Andrew Brackmann

us that, that [indiscernible]? to anything be might level that around is start Valerie, to on You this Andrew your talk could today. products announced development with you in guess this technology share your did is say maybe the about questions. you just there related today. taking done has on the Maybe confidence of that I Thanks the This and market? sort to been partnership for able of to bringing like work

Valerie Palmieri

Andrew, Hi Thank joining. afternoon. you for good

your was it I was your going line or in a it's little don't line. I'm and so Your line bit, out line. our know hoping

it the is the microRNA it's two has studying published. papers of Dana spent have of there ago started partnership years, This in things, focused can earnings a a terms Brigham evaluating as panel. a and on script, well their of collection and that Harvard, you is Farber years University so we of Lodz number high-risk couple been a as of a a couple really panel, of hear So technology the as and population.

with papers they as And said, significant specific So this for two at is technology looking PPV. high-risk a those panel I patients. published

the it's very patients study We of but stated early about domain, specificity. XX% and XXX it very was significant and you can public papers is in of haven't study done stage. send high that the and initially that PPV The PPV was about we

Andrew Brackmann

viable that be that commercially here? it's just of here and we then Could context about early maybe that guess, I around product? still in just you of and maybe that. following should levels for uptick thinking development you thanks work. sensitivity think and early recognizing up pretty Great, for really at performance And needed are specificity stage provide some brought test levels for what

Valerie Palmieri

specificity aiming So out, thought side, our get things kind in I we the say came two I to are are on right, guidelines would to the what say that screening that colorectal Ideally, and metrics like is of lower XX.XX% something XX%. the we aiming want that up that just performance for. to XX.XX% that honestly, we'd I range. is But

Andrew Brackmann

of and year? initiatives here. the with thinking Perfect. taking OpEx One, Thanks throughout be for And for XXXX a that of Didn't and question. then, burn should about the number for pacing we you. ongoing, how Bob, forget cash about the you one just

Robert Beechey

over So to but that as think team also going will as phased looking we some if we a that that IT by I high I going out, drive new well we're hospital will, And edge be digits. the investment, bit the QX we're on really the little it's when that's single think not R&D. spending the care. be this think at I in view investment those And the face revenue of standard offset group to not area as expanding and driver the kindly was were of you I have cost the that think the where to hires reference that's fact on, dramatic, QX

think I revenue in over terms start lot those phasing of those as So in the the themselves. that quarter, third be will to pay hospital investments a for will turn to group starts and time

really So short-term a bubble I think it's fairly relatively and modest.

intention very be terms measured did raise of to staying and did, in want when positive. recent is that stated cash bridge this we're having with deal objective our Our we flow to the That us it that. was to we we

Operator

[Operator Cantor from Kyle Instructions] with comes next line Fitzgerald. Our Mikson of the question

your You may proceed question. with

Kyle Mikson

OVASight on acceleration. wanted I So start to the

it's please it about size much I'll would on help guess ultimately? talk terms love a I like that different in sales lot about I the than here what then GenetiX, pricing, could of so will would it and versus be I for any ASP, in I force said help a typical that, I But test like four think so for the that market color. times I So OVAXplus? past. $XXX, there. monitoring if two training guess, you be think lower leave you And want me - be Thanks OVASight to how a just times that could a the the few the year, and And understand really a think to

Valerie Palmieri

problem. No

to then fill as start So I'll well. in Kaile and let going Kyle, I'm

terms in sales points. the of the call same of training it's So force,

masses something assessment the So of we are doctor are is to terms in pre-menopausal we in and with not October, surgery. to that number those had to want surgery. really go of mind. they that through that paper saw doctor and COVID, conservative largest a surgery, woman where of are management to patients is Keep been assesses we actually mind those for published selling a point, one, do actually we've move women same looking did recently not and call top the of a understand do who really seeing lot a a during surgery doctors a to forward a test product so number low-risk our risk that which percentage of we in is for What where of large and the had fertile, patients pelvic women that

ASP. terms The like OVA. rolling be did AMA we we So a just that's we version going of with number code of but ASP will initially, Number an initially more one. stats be that in for out, two, will be Code,

we've there'll it's Keep in so out want will OVASight product the on be test be is So be a just I going initially I to be rolling OVA. make clear be trial. for discounts not initial three think product that that will year. we that similar pricing monitoring. envision it that per crosswalk that serial some because this times cohorts to to do the a on will are two four mind to we an

assessment benign those an for first The planned of masses patients surgery. is risk are of the not for cohort malignancy

So can once, it's product. If serial one-time it use. monitoring more But the this be next use they a the our doctor so. of do elects revision to a of will than use

we X and the TAM, TAM subjective to million have that million out going patient to product say would will rolling we per initially, be the be doctor I then X.X the in women terms that the rolling out be back year. X the that So use times X.X per that to the to of of will again will

just on be place the for Kaile training that comment wants to So is putting to in she this new going product.

Kaile Zagger

so we involved the the Hi, be team actively June. thank training market a not constructing will the as in getting Yes, strategy, robust next field in now you go over months six right field but place we of strategy much. have to be the we'll and this only marketing

the do everyone penetrate rapidly as have of adoption that understanding segmentation drive time approaching that new we possible. up market this, and So to three-month are how a to care can speed so quickly and we of on integrated, the products, standard as we towards getting getting lead

Valerie Palmieri

your that answer Kyle? Did questions,

Kyle Mikson

force answering, Yes. just on And further, actually. Kaile, great. stick the a Valerie with and thanks and sales little bit a for that was lot

they just XX you So where quarter you think stand be because will there's the like out converted XX%, will be kind where the I to if then new I will - rolling about on product increased it training I those and to talk XX, you're… different currently guess you of could typical currently - like would that going the synergy, think take of you're where like kind heard I a to reps, when prioritized lot in guess then the and six things months about and second where of will

Valerie Palmieri

it simplify for me Let you.

have the a we had GYN. what is so it's one, calling on So same the call point, number we that's XX,

and that have then their in a initial ultrasound come hospital the team there's go and actually lot then level, We urology, to have of the these women at because women GI GYN. orthopedic a

hospital, we So into pathway go and I'll a Kaile to want do let actually in horizontal care the that.

in to team this us XX is time, we XX team the So of, I see sales hospital all of the a let's core say, in not over and then be of core, team hospital. closer to And see time, evolving in from, year, today that XX. going terms a this it's to and over initially but going team, and

where have now. in we right add So the methodically haven't we we're that served been served going markets to not

that were going the hospital really New the have are Those we've Medicaid on the we've and contract advocates like system. last for relay who community. where are level the we be a We physicians the to in now having double and states we swell built returning very in are at going York year physicians this the now hospital down also got community both now between to efficient

Dr. healthcare the Kaile, the to have Ratner individuals these institutions. on bringing discipline is - the with convert So and who Yale, chief two the section at knowhow

the protein, hospitals we've at the and path community-based to place actually run parallel got get and to share really addition the in to a that we but synchronized level. is and that adoption core parallel at So path feel market well additional in

So give I'll comment to details. let Kaile more the you also on hospital strategy

Kaile Zagger

Thank you, Valerie.

add the So some and around I tactical strategy structure. can specifics the

care. is So creating to of a it pillar essentially approach five standard

which standard Valerie care adopt We be the this new have the core to the is offices, the team, into there that is of hospital the CAXXX. spoke then for to disrupting and rapidly will help about, there net approach that working integrate GYN system as and first currently the team is

third of that team. integration The leader is pillar our

comprised is the integrate to synergy how the they into is workflow, to this in dive informatics force. the clinicians into understand how then and how to pillar so sales Fourth overlays team So EMR. and such in process background a clinicians, of expertise assess as informatics,

be together as our will super three-pronged a deployed care. is standard will all driven environment approach certain it's health as marketing of targeted codes, the that that well disrupt care in and commercial around of approach is CAXXX heavily we environments have. applicable fifth and The covered decentralized which into activation pillar a we've pillar, matrix be working groups, So contracts ICD-XX lives this that data to and the the platform,

we're sales places synergy an really that approach core and few one we've sales working So the integration a rep, all collective territories of with counterpart first will territories North in to and hospital eventually rep, metrics. then the strongest structured the coupled be a covers lead comprised that America one

Valerie Palmieri

the of overall terms plan. in given Kyle, So

Kyle Mikson

Brigham and Yes, a the I wanted as was partnership touch Lodz on to lot. Thanks Dana-Farber that fantastic. And well.

that sounded color there new if part the any partnership can you ultimately the kind of like role could do just So about confirm economics will play the will research just it about talk And the you mean years? the I know good mRNA you. an Thank oversight ultimate going groups then would over of those regulatory technology be thinking next, the at it's that possibly like in cash results inherent the - collaboration, commercialization, think if you from And all. the but product process, great. that but be I of sense, be to a panel then OVAInherit? makes that that about plus outlay the

Valerie Palmieri

would it's you're pretty Okay. say Kyle, do. I

So let Dr. let in. fill I'll and Northrop me start

this to collaboration experts cancer research I risk want and with say, high is a early So ovarian detection.

published They've have panel. two as on stage. said, So XX% this spent a early they I XXX about number patients years honing of a, papers

microRNA Our protein our with to a algorithm. have and combined to actually goal component is couple take it this

economics to going and the your now of are just starting we combination, but back in already we so to getting be that of of negotiated And at proof call terms then the question. I additional, will we've concept point,

exclusivity engine, that combines like Hopkins will and will the will that we pay and their be be to we in a paying also commercialization our So have Johns a we similar we technology. to them the product product, will royalty be technology

spending, are I'll technology. on say to with us then own on comment let taking developing So also this on folding instead Northrop and our specimens this I want of is in and so our plus Dr technology are a our these we way jumpstarting years as with rare, well. their us, OVAInherit of

Lesley Northrop

Valerie. you, Thank

so we the exciting proteomics things the I that with of the transcriptome that's think same unique can use one about sample is type. coupling the

to serum that's profile. same we're and the of the is and protein survival the to doing patients and getting a identify be able that the they this combination use sample the from be well in disease where the can that this, the accuracy diagnostic really the going cancer have to ovarian before unique by we as indicative profile capture And expression patient microRNA as able early both get we're of so stage, rate. higher So

type, The these other two targets the beauty of from can sense that on sample same it we combine we is platform. the it same technology

technology two we that this so so we can the not can create to our in able so throughput can volume, way, smaller this micro platform using sampling. we're what's sample we blood high use use separate same that this being combine we a technology so the And laboratory. about optimize point technology, unique then called technology on is by can the process And at last like

the actually So and patient to could is in the their clinic clinician patient. could launch having we opportunity DTC versus this to a that eventually consent actually home what like test so to we model, sampling access utilize for go directly do

really the for cancer. broaden able can ovarian it way disease for is this population, So we risk harnesses to so test us on all that the and patient really women at

Kyle Mikson

a that me. one or emphasis term guess, just be okay if number? the may was the XXX live And you're I near of priority million are the will from expanding just coverage initiatives, lives, for in payer just in all I if the I if these kind XXX on covered updates with With wondering - last question I

Valerie Palmieri

fast So what Kyle, for resources are more put I to it would only products these to that a, on say market looking not that fashion. call, but coming actually in OVA, we're I

that So the EndoCheck begins OVAInherit into oversight work reimbursement go that now. as well to needs strategy as

spinal paid are we we don't and our get if reimbursement designing is trials in mind, study and our yes, first that we cord the of foremost protocols. don't change practice, So

that out we're have the as and and products, even data on long looking outcomes at they're supercritical have studies our OVA we Philippines initiating absolutely XX studies So the that and of coming XX-month plus outcome with clinical Israel. utility

will this year we So studies published within those be believe.

Operator

today's we gentlemen, reached end over closing Valerie to the to have turn remarks. back of Palmieri question-and-answer I call session. this and Ladies Ms. would for like

Valerie Palmieri

in progress With of within to ours and portfolio long-term increased QX, in differentiated is the now our subside, see our we point the as organization into believe under commercial lives and guideline right we will COVID will believe and are sustainability footprint, things be the believe of test continued we by we restrictions test, for three and we and call closing, a which to poised do and will XX% in a continue XXXX vaccinations place the profitability. same a drive coverage, In value. to growth support growth differentiate strong position

Women's science is we health to tools, and goal appreciate a end your overall patient and support market, you large with a in which mass to proprietary Our platform global and joining each with women's Health. Thank we serve. and the better serve pelvic today population data in for health well-being coupled Aspire drive us interest will

Operator

This concludes today's conference.

for and You disconnect your at your your you time. rest enjoy evening. lines Thank of the participation this may

Aspira Women's Health (AWH) 26 Mar 212020 Q4 Earnings call transcript